Hepatitis B virus (HBV) is a serious global health problem. The development of a safe and effective vaccinewould help infection prevention. Previous hepatitis B vaccine production involved the isolation of the noninfectious particle from chronic HBV carriers. DNA recombinant technology has been used for vaccineproduction without having been contaminated with blood-born infectious ag...

Hepatitis G virus/GB virus-C (HGV/GBV-C) is a newly identified Flavivirus. Its clinical significance in chronic hepatitis B and C remains controversial. Infection with HGV/GBV-C was surveyed in 500 blood donors, 130 patients with chronic hepatitis B and 173 with hepatitis C, with chronic liver disease, cirrhosis, and/or hepatocellular carcinoma (HCC). HGV/GBV-C RNA was detected by reverse trans...

Introduction: Hepatitis B is a disease caused by the hepatitis B virus (HBV), which is transmitted through percutaneous (i.e., puncture through the skin) or mucosal (i.e., direct contact with mucous membranes) exposure to infectious blood or body fluids. HBV can cause chronic infection, resulting in cirrhosis of the liver, liver cancer, liver failure, and death. Persons with chronic infection a...

Hepatitis a general term which refers to inflammation of the liver. It may result from various causes, both infectious ( viral, bacterial, fungal, and parasitic) noninfectious (alcohol, drugs, autoimmune diseases, metabolic diseases). The hepatitis B X protein (HBx) plays role in epigenetic regulation HBV replication. Real-time PCR has catalysed wider acceptance because it is more rapid, sensit...

INTRODUCTION The FEM-PrEP trial was a pre-exposure prophylaxis clinical trial to test the safety and efficacy of Truvada (tenofovir disoproxil fumarate and emtricitabine) in the prevention of human immunodeficiency virus infection. Because Truvada can suppress hepatitis B virus replication, and withdrawal of Truvada can cause hepatic flares in patients with chronic hepatitis B, pre-enrollment s...

Liver disease has a worldwide distribution.(1,2) Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis and primary hepatocellular carcinoma in most parts of the world. In the developing countries of Asia and Africa, though hepatitis B virus (HBV) infection is the commonest cause of chronic liver disease, HCV is fast evolving as an equally important infection among these popu...

The treatment goal for chronic hepatitis B is true eradication of the hepatitis B virus, but this is rarely achieved with first-line treatment regimens because of an inability to disrupt covalently closed circular DNA and an inadequate host immune response. Therefore, new antiviral agents are needed to target various stages of the hepatitis B virus lifecycle and modulation of the immune system....

the burden of exposure to blood-borne pathogens (such as hepatitis b and c viruses) is considerable for health care workers. hepatitis virus transmission requires a non-immune host, an infectious source, and skin or mucous membrane injury. these three aspects are the main fields for preventional interventions. we reviewed major recent studies on this topic to identify precautions health care wo...